Genomenon was named the 2020 Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan today. The distinguished award highlights the superiority of Mastermind as a pioneering and first-in-class genomic database and leading research tool accelerating precision medicine. Below is the report in its entirety.
Happy 2020! We’re starting out the year with some new features in Mastermind: Personalize Your Dashboard with Locking Panes You can now lock detail panes open or closed to customize how you like to view the data in the Mastermind dashboard.
Beta-propeller Protein-Associated Neurodegeneration, or BPAN, is a rare genetic condition caused by mutations in the WDR45 gene. It is characterized by seizures, complex epileptic encephalopathies, developmental delays, and neurodegenerative symptoms similar to those found in Parkinson’s disease and currently has no cure.
Genomenon Founder & Chief Science Officer, Dr. Mark Kiel, was a guest speaker at the 2019 Cutting Edge Drug Discovery & Development Symposium in Ann Arbor, Michigan on ‘Curating the Genome to Drive Drug Discovery’. Below are his slides and a transcript of his talk.
Fusion genes have long been known to play an important role in the development of cancer. Identifying and documenting each newly discovered fusion is crucial in both patient diagnosis and the development of Precision Medicine.